First Patients Are Enrolled In a Phase IIa Study of a Blood Substitute

OCT is conducting a multicenter blind randomized trial to evaluate clinical effectiveness and safety of the investigational infusion medication, that sought to become an alternative to the existing blood transfusions in cases of acute blood loss.

Study participants include 60 patients of both sexes aged from 18 to 65 years. The aim of this trial is to assess the drug’s effectiveness, tolerability and toxicity as well as to establish optimal dosage by comparing the effect of two therapeutic doses.

For this project, the OCT team attracts more than 10 research centers operating in Russia, and assumes responsibility for medical writing, logistics, project management and monitoring.
Back to the list